Frontiers in medical technology最新文献

筛选
英文 中文
Utility of 3D facial analysis as a biomarker in rare diseases exploration with hereditary angioedema. 三维面部分析在遗传性血管性水肿罕见病诊断中的应用。
IF 4.6
Frontiers in medical technology Pub Date : 2026-09-23 eCollection Date: 2026-01-01 DOI: 10.3389/fmedt.2026.1857918
Saumya Jamuar, Richard Palmer, Haur Yueh Lee, Faith Li-Ann Chia, Choo Beng Goh, Stuart Lee, Petra Helmholz, Shermaine Chan, Gareth Baynam
{"title":"Utility of 3D facial analysis as a biomarker in rare diseases exploration with hereditary angioedema.","authors":"Saumya Jamuar, Richard Palmer, Haur Yueh Lee, Faith Li-Ann Chia, Choo Beng Goh, Stuart Lee, Petra Helmholz, Shermaine Chan, Gareth Baynam","doi":"10.3389/fmedt.2026.1857918","DOIUrl":"10.3389/fmedt.2026.1857918","url":null,"abstract":"<p><strong>Background: </strong>People living with rare diseases (PLWRD) often face significant challenges in receiving timely and accurate diagnoses, leading to what is known as a diagnostic odyssey. Digital phenotyping (DP) offers a promising solution by leveraging advanced technology to capture unique digital signatures associated with various rare diseases. This innovative approach not only aids in the identification of these conditions but also facilitates the detection of digital biomarkers (DBM). By utilizing DP and DBMs, we can improve both the diagnosis and management of RDs, ultimately leading to better health outcomes for affected participants.</p><p><strong>Objective: </strong>To identify whether DBMs can be identified by DP utilizing 3D facial imaging techniques in outpatient settings in participants with RDs.</p><p><strong>Design setting and participants: </strong>This multicentre observational study was conducted in 3 hospitals in Singapore. The eligible participants were male and female RD participants of various age groups. The study duration was 4 years and 8 months.</p><p><strong>Interventions: </strong>Twenty participants of Chinese genetic ancestry were photographed using a 3D camera. Additionally, two participants with hereditary angioedema (HAE) were photographed during acute stages of disease flare-ups.</p><p><strong>Main outcomes and measures: </strong>The obtained facial scans of participants (that included participants with HAE in non-acute phase) were plotted using Artificial Intelligence-powered software - Cliniface. The growth curves and facial landmarks obtained were compared against the growth curves of normal RD-unaffected individuals of Chinese genetic ancestry. The two participants with HAE were photographed qualitatively over a longer period of time, and their scans were plotted, yielding growth curves.</p><p><strong>Results: </strong>Distinct facial markers such as periorbital swelling were identified in two qualitatively assessed HAE participants during flare-up stages. This provides an opportunity to explore and validate whether these facial signatures in a disease condition can be assigned as DBM for HAE.</p><p><strong>Conclusions: </strong>and relevance: This study explores the utility of 3D facial analysis as a DBM in rare diseases such as HAE. These findings offer preliminary objective evidence that supports existing subjective reports of facial features in the literature. Additionally, while DP's diagnostic capabilities may be limited, it successfully identified DBM, which could facilitate disease monitoring in conditions such as HAE.</p>","PeriodicalId":94015,"journal":{"name":"Frontiers in medical technology","volume":"8 ","pages":"1857918"},"PeriodicalIF":4.6,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13642716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149129583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From sepsis biomarker discovery to regulated in vitro diagnostics: evidence, certification status and implementation gaps. 从败血症生物标志物发现到受控体外诊断:证据、认证状态和实施差距。
IF 4.6
Frontiers in medical technology Pub Date : 2026-09-22 eCollection Date: 2026-01-01 DOI: 10.3389/fmedt.2026.1916860
Erika P Plata-Menchaca, Enrique Hernández-Jiménez
{"title":"From sepsis biomarker discovery to regulated <i>in vitro</i> diagnostics: evidence, certification status and implementation gaps.","authors":"Erika P Plata-Menchaca, Enrique Hernández-Jiménez","doi":"10.3389/fmedt.2026.1916860","DOIUrl":"10.3389/fmedt.2026.1916860","url":null,"abstract":"<p><p>Sepsis remains a diagnostic challenge because early clinical manifestations are non-specific and microbiological confirmation often arrives too late to guide first-hour decisions. The 2026 Surviving Sepsis Campaign guidelines reinforce early clinical recognition using validated clinical scores, appropriate diagnostic strategies, and responsible antimicrobial use and de-escalation. Yet, initial management still frequently occurs under diagnostic uncertainty. Hundreds of biomarkers have been proposed to improve sepsis diagnosis, risk stratification and treatment guidance; however, only a limited subset has progressed from discovery to regulated <i>in vitro</i> diagnostic use. This Mini Review examines selected sepsis biomarkers and diagnostic platforms with emphasis on technologies that have reached certified or cleared IVD implementation, or that illustrate a credible route toward regulated use. We discuss conventional soluble biomarkers such as procalcitonin, C-reactive protein, interleukin-6 and lactate; emerging severity and host-response markers including presepsin, pancreatic stone protein, monocyte distribution width and mid-regional proadrenomedullin; transcriptomic and cellular host-response tests; and functional immune technologies such as the LPS-induced TNF-alpha release assay, also referred to as TARA. Rather than ranking biomarkers solely by diagnostic performance, we emphasize intended clinical use, biological rationale, sample type, turnaround time, regulatory status and workflow compatibility. The review highlights the persistent gap between biomarker discovery and clinical deployment, set against an evolving regulatory landscape shaped by the EU IVDR and the phased rollout of EUDAMED. Future sepsis diagnostics will likely move beyond isolated inflammatory analytes toward integrated host-response, near-patient and functional immune assays able to support early triage, risk stratification, antimicrobial stewardship and precision immune monitoring.</p>","PeriodicalId":94015,"journal":{"name":"Frontiers in medical technology","volume":"8 ","pages":"1916860"},"PeriodicalIF":4.6,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13639665/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149120796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Approval lag and loss for biologic-device combination products in Japan and the United States. 生物器械组合产品在日本和美国的审批滞后和损失。
IF 4.6
Frontiers in medical technology Pub Date : 2026-09-18 eCollection Date: 2026-01-01 DOI: 10.3389/fmedt.2026.1924169
Makiko Mochizuki, Hideki Maeda
{"title":"Approval lag and loss for biologic-device combination products in Japan and the United States.","authors":"Makiko Mochizuki, Hideki Maeda","doi":"10.3389/fmedt.2026.1924169","DOIUrl":"https://doi.org/10.3389/fmedt.2026.1924169","url":null,"abstract":"<p><strong>Introduction: </strong>The market for drug delivery devices (DDDs), including combination products that integrate pharmaceuticals and medical devices, has expanded rapidly with the increasing use of biopharmaceuticals and growing adoption of self-administration. However, the extent and causes of approval lag and approval loss for device presentations, defined as presentations approved in one country but unavailable in the other, have not been systematically evaluated between Japan and the United States.</p><p><strong>Methods: </strong>We analyzed approvals of biopharmaceuticals in various device presentations, including prefilled syringes (PFS), autoinjectors, multidose pen injectors, on-body injectors (OBIs), and cartridge formulations, using the Pharmaceuticals and Medical Devices Agency (PMDA) and U.S. Food and Drug Administration (FDA) databases from 2000 to 2025.</p><p><strong>Results: </strong>Among 176 biopharmaceutical products approved in the United States, 16% were not approved in Japan. However, most cases were attributable to approval loss by drug, reflecting products whose active substances were not approved for the Japanese market, rather than approval loss by device presentation. Although median approval lag tended to vary across device presentations, with multidose pen injectors and cartridge presentations showing median delays exceeding approximately two years and autoinjectors showing the shortest lag at approximately 10 months, these differences were not statistically significant. Statistical analyses using Pearson's chi-square, Fisher's exact, and Kruskal-Wallis tests showed no significant differences in device presentation approval between Japan and the United States after excluding products lacking active substance approval in either country (<i>p</i> = 0.961 and 0.963), or in approval lag among device presentations in Japan-first and U.S.-first products (<i>p</i> = 0.088 and 0.299).</p><p><strong>Discussion: </strong>In the United States, multiple device presentations were often approved simultaneously, whereas Japan more frequently adopted a stepwise approval approach. Differences in the regulatory scope of combination products and co-packaging requirements also contributed to country- specific packaging, potentially prolonging pre-approval preparation and increasing supply chain complexity. Overall, regulatory approval discrepancies between Japan and the United States were driven primarily by drug loss rather than device presentation loss. Accelerating drug approval, promoting simultaneous development of multiple device presentations, and enhancing regulatory harmonization for combination products may reduce approval lag by device presentation and improve patient access.</p>","PeriodicalId":94015,"journal":{"name":"Frontiers in medical technology","volume":"8 ","pages":"1924169"},"PeriodicalIF":4.6,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13630725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149120735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Independent testing infrastructure for new approach methodologies: the UC Davis NAMs testing center. 新方法的独立测试基础设施:加州大学戴维斯分校NAMs测试中心。
IF 4.6
Frontiers in medical technology Pub Date : 2026-09-04 eCollection Date: 2026-01-01 DOI: 10.3389/fmedt.2026.1966220
K C Kent Lloyd
{"title":"Independent testing infrastructure for new approach methodologies: the UC Davis NAMs testing center.","authors":"K C Kent Lloyd","doi":"10.3389/fmedt.2026.1966220","DOIUrl":"10.3389/fmedt.2026.1966220","url":null,"abstract":"<p><p>As biomedical research moves toward greater use of human-based experimental systems, the practical problem is no longer simply how to develop new models, but how to determine when they are valid and predictable for a particular use. Independent testing infrastructure can help make that determination. The UC Davis NAMs Testing Center is one model for bringing comparative biology, engineering, clinical and computational expertise together to evaluate NAMs for defined biomedical research purposes.</p>","PeriodicalId":94015,"journal":{"name":"Frontiers in medical technology","volume":"8 ","pages":"1966220"},"PeriodicalIF":4.6,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13585975/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149009634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Roles in brain stimulation, recording and interpreting neuroimaging data: a systematic survey of 26 countries on current practices in EEG, MRI, TCD, TMS and FUS. 脑刺激、记录和解释神经成像数据的作用:对26个国家的脑电图、MRI、TCD、TMS和FUS的现行做法进行系统调查。
IF 4.6
Frontiers in medical technology Pub Date : 2026-09-04 eCollection Date: 2026-01-01 DOI: 10.3389/fmedt.2026.1917621
Vugar Valizada, Leon Daði Sesseljuson, Raffaele Nardone, Aljoscha Thomschewski, Eugen Trinka, Yvonne Höller
{"title":"Roles in brain stimulation, recording and interpreting neuroimaging data: a systematic survey of 26 countries on current practices in EEG, MRI, TCD, TMS and FUS.","authors":"Vugar Valizada, Leon Daði Sesseljuson, Raffaele Nardone, Aljoscha Thomschewski, Eugen Trinka, Yvonne Höller","doi":"10.3389/fmedt.2026.1917621","DOIUrl":"10.3389/fmedt.2026.1917621","url":null,"abstract":"<p><strong>Introduction: </strong>Clear role definitions in performing and interpreting neurophysiological and neuroimaging procedures are essential for patient safety and diagnostic accuracy. There is currently no comprehensive overview of the international landscape of health professionals responsible for these tasks. In the present review, we aimed to summarize local practices for electroencephalography (EEG), brain magnetic resonance imaging (MRI), transcranial magnetic stimulation (TMS), transcranial Doppler (TCD), and focused ultrasound stimulation (FUS).</p><p><strong>Methods: </strong>We systematically searched scientific literature, national health organizations websites, and contacted local health authorities from 26 countries.</p><p><strong>Results: </strong>EEG and brain MRI are typically performed by technicians and interpreted by physicians (neurologists or radiologists). TCD is performed and interpreted predominantly by physicians, since it requires real-time evaluation. Single-pulse TMS is either performed by physicians or requires the presence of physicians when the procedure is performed by a technician. The interpretation is done by physicians. Despite existing international recommendations, there is a significant absence of local guidelines for responsibilities in performing and interpreting TMS and FUS. In countries with information available, therapeutic use of rTMS, and FUS is performed by physicians (neurologists, psychiatrists, or surgeons).</p><p><strong>Discussion: </strong>The development of standardized national protocols is needed to ensure patients' safety and diagnostic accuracy in clinical settings for TMS and FUS.</p>","PeriodicalId":94015,"journal":{"name":"Frontiers in medical technology","volume":"8 ","pages":"1917621"},"PeriodicalIF":4.6,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13585712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149009558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dual-branch hierarchical fusion network for voice-based classification of type 2 diabetes mellitus using multi-vowel acoustic features. 基于多元音声学特征的2型糖尿病语音分类双分支层次融合网络。
IF 4.6
Frontiers in medical technology Pub Date : 2026-09-03 eCollection Date: 2026-01-01 DOI: 10.3389/fmedt.2026.1908856
Pengxu Jiang, Wenke Zhang, Aiqin Li, Peng Li
{"title":"Dual-branch hierarchical fusion network for voice-based classification of type 2 diabetes mellitus using multi-vowel acoustic features.","authors":"Pengxu Jiang, Wenke Zhang, Aiqin Li, Peng Li","doi":"10.3389/fmedt.2026.1908856","DOIUrl":"10.3389/fmedt.2026.1908856","url":null,"abstract":"<p><strong>Problem: </strong>While voice-based analysis has emerged as a potential non-invasive approach for exploring acoustic alterations associated with Type 2 Diabetes Mellitus (T2DM), current approaches often fail to fully capture disease-relevant vocal patterns due to simplified recording protocols and insufficient feature modeling.</p><p><strong>Aim: </strong>This study aims to investigate the feasibility of voice-based classification of T2DM using a multi-feature fusion framework, leveraging sustained vowel phonations and integrating multiple acoustic feature types to enhance diagnostic performance.</p><p><strong>Methods: </strong>Voice recordings were collected from 378 participants, including T2DM patients and healthy controls. Each participant pronounced six Mandarin vowels, from which acoustic features-including Mel-frequency cepstral coefficients (MFCCs), glottal parameters, and eGeMAPS descriptors-were extracted. Neural networks, including convolutional and deep architectures, were applied to capture pathology-relevant segments. Vowel-level fusion modules aggregated features across vowels, and an attention-based hierarchical fusion mechanism combined the three feature types, adaptively emphasizing features most relevant to T2DM.</p><p><strong>Results: </strong>The proposed dual-branch hierarchical fusion model achieved 80.48% detection accuracy.</p><p><strong>Conclusion: </strong>These results suggest that sustained vowel phonations contain potentially informative acoustic patterns associated with T2DM status. However, further validation using independent cohorts is required before clinical application.</p>","PeriodicalId":94015,"journal":{"name":"Frontiers in medical technology","volume":"8 ","pages":"1908856"},"PeriodicalIF":4.6,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13582493/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148993063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quantum-edge synergy for dynamic acoustic compensation in ultrasound safety: a narrative review of tissue heterogeneity challenges. 超声安全中动态声学补偿的量子边缘协同:对组织异质性挑战的叙述回顾。
IF 4.6
Frontiers in medical technology Pub Date : 2026-09-03 eCollection Date: 2026-01-01 DOI: 10.3389/fmedt.2026.1775679
Bin Hu, Wei Shi, Shihong Xiong, Songlin Li, Kelun Wang, Na Gong
{"title":"Quantum-edge synergy for dynamic acoustic compensation in ultrasound safety: a narrative review of tissue heterogeneity challenges.","authors":"Bin Hu, Wei Shi, Shihong Xiong, Songlin Li, Kelun Wang, Na Gong","doi":"10.3389/fmedt.2026.1775679","DOIUrl":"10.3389/fmedt.2026.1775679","url":null,"abstract":"<p><strong>Background: </strong>Conventional ultrasound safety monitoring relies on the Mechanical Index (MI) and Thermal Index (TI), which lack tissue-specificity. Consequently, real-time safety profiling remains imprecise. Dynamic, tissue-specific corrections such as tissue perfusion rate (TPR) aim to address this limitation. This narrative review examines how integrating these corrections with quantum-cloud computational frameworks may enable enhanced safety and image quality in ultrasonic applications.</p><p><strong>Objective: </strong>We assessed the potential of an integrated quantum-cloud framework to reduce ultrasound-related bioeffects without compromising image quality, compared to standard MI/TI monitoring in patients undergoing clinical ultrasound imaging.</p><p><strong>Methods: </strong>A narrative synthesis of the eligible literature was performed, guided by thematic analysis frameworks. Quantitative outcomes were descriptively summarized with medians and ranges; formal meta-analysis was not conducted because heterogeneity in TPR measurement protocols, device manufacturers, and outcome definitions violated the commutability assumption required for statistical pooling.</p><p><strong>Results: </strong>Qualitative synthesis indicated that tissue-specific, multi-parameter correction strategies were consistently associated with more conservative acoustic exposure and heightened safety awareness than static MI/TI monitoring alone, although the consistency and clinical magnitude of these benefits varied across anatomical applications and study designs. The certainty of the current evidence was judged low to moderate, limited by non-standardized TPR measurement protocols and heterogeneous outcome definitions.</p><p><strong>Conclusions: </strong>Together, these data suggest that multi-parameter acoustic correction coupled with cloud computing holds promise for improving ultrasound safety profiling and imaging precision. However, the current low-to-moderate certainty of evidence, due to methodological heterogeneity, necessitates future validation of edge-cloud synergies to realize robust, personalized monitoring systems.</p>","PeriodicalId":94015,"journal":{"name":"Frontiers in medical technology","volume":"8 ","pages":"1775679"},"PeriodicalIF":4.6,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13581935/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148993110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An evaluation of pathology foundation models with weakly supervised learning for BRAF mutation prediction in melanoma whole slide images. 基于弱监督学习的病理基础模型在黑色素瘤全幻灯片图像中用于BRAF突变预测的评估。
IF 4.6
Frontiers in medical technology Pub Date : 2026-09-03 eCollection Date: 2026-01-01 DOI: 10.3389/fmedt.2026.1835452
Lucy Godson, Jack Breen, Alexander I Wright, Derek Magee, Daljeet Bansal, Darren Treanor, Emily L Clarke
{"title":"An evaluation of pathology foundation models with weakly supervised learning for BRAF mutation prediction in melanoma whole slide images.","authors":"Lucy Godson, Jack Breen, Alexander I Wright, Derek Magee, Daljeet Bansal, Darren Treanor, Emily L Clarke","doi":"10.3389/fmedt.2026.1835452","DOIUrl":"10.3389/fmedt.2026.1835452","url":null,"abstract":"<p><strong>Introduction: </strong>Melanoma is the most aggressive form of skin cancer, with around 40-50% of cases harbouring BRAF mutations that can be effectively targeted to improve patient outcomes. Typically, BRAF mutations are identified through DNA sequencing, which can be costly and contribute significantly to turn-around-times. Predicting BRAF status directly from haematoxylin and eosin (H&E) whole-slide images (WSIs) could offer a faster and more accessible alternative within digital pathology workflows.</p><p><strong>Methods: </strong>In this study, we evaluated six pathology foundation models for WSI-based BRAF mutation prediction using an attention-based multiple instance learning (ABMIL) framework. Training and testing models with five-fold cross-validation, using 1,109 WSIs from 745 patients and performing external validation with TCGA and VisioMel cohorts.</p><p><strong>Results: </strong>Models which utilised H-Optimus-1 features achieved the highest AUROC values on the internal test set (0.80 (0.72, 0.88)) and VisioMel (0.79 (0.75, 0.83) external test set, while UNI2-h features demonstrated superior sensitivity and higher TCGA performance (AUROC: 0.76 (0.66, 0.86)). Subgroup analyses indicated that model performance was impacted by histopathological features such as ulceration and tissue area, while t-SNE plots showed that high-attention foundation model features tended to cluster based on the dataset the features were from, rather than biological signal.</p><p><strong>Discussion: </strong>Overall, foundation models combined with weakly supervised learning provide competitive performance for BRAF status prediction in melanoma WSIs, but our findings highlight the need for diverse melanoma datasets and the importance of evaluating model performance beyond a single metric when developing H&E-based computational biomarkers.</p>","PeriodicalId":94015,"journal":{"name":"Frontiers in medical technology","volume":"8 ","pages":"1835452"},"PeriodicalIF":4.6,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13582659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148993083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systematic review of 3D-printed surgical devices for austere environments: an evaluation guideline. 恶劣环境下3d打印手术器械的系统评价:评估指南。
IF 4.6
Frontiers in medical technology Pub Date : 2026-09-02 eCollection Date: 2026-01-01 DOI: 10.3389/fmedt.2026.1908227
Kyung-Hoon Moon, Matthew Cant, Mehdi Saeidi, Arul Ramasamy, Anthony M J Bull
{"title":"Systematic review of 3D-printed surgical devices for austere environments: an evaluation guideline.","authors":"Kyung-Hoon Moon, Matthew Cant, Mehdi Saeidi, Arul Ramasamy, Anthony M J Bull","doi":"10.3389/fmedt.2026.1908227","DOIUrl":"https://doi.org/10.3389/fmedt.2026.1908227","url":null,"abstract":"<p><strong>Background: </strong>Three-dimensional (3D) printing is a common manufacturing technique. It is being adopted to produce essential surgical equipment in austere settings around the world. However, the evaluation of these products remains inconsistent. This raises safety concerns and limits translation to clinical use. To address this, this systematic review aims to identify 3D-printed surgical devices intended for austere environments and examine their evaluation methodologies. The findings will inform the development of an evaluation framework that supports the design of patient-safe devices.</p><p><strong>Methods: </strong>Medical and engineering bibliographic databases were searched to identify literature describing 3D-printed surgical devices for use in austere environments. Two independent blinded reviewers screened articles in two stages using abstracts and full texts. The review was conducted in accordance with PRISMA guidelines. In line with the EU Medical Device Regulation, device evaluations were categorised into manufacturing specifications, mechanical performance, sterilisation, biocompatibility, and usability. Reported methods of device evaluation were extracted and compared against the relevant published standards.</p><p><strong>Results: </strong>15 studies met the inclusion criteria. The austere environments included low-middle income countries, military settings, and space exploration. 13 out of 15 studies used Fused Deposition Modeling printers. All materials were thermoplastic. Printed equipment ranged from external fixators to surgical sets. The printing details were well reported. However, there was inconsistency in testing methods, resulting in data that is incomparable across the studies. 2 of 15 papers conducted mechanical testing for external fixators using American Society for Testing and Materials standards but used different parameters. 2 studies used self-developed mechanical testing protocols. 7 of 15 papers reported usability analysis using various methodologies. 3 of 15 papers described testing for sterilisation of the equipment, but only one paper evaluated its effect on the device. There was no biocompatibility testing.</p><p><strong>Conclusion: </strong>Despite the potential implications for patient safety, all 15 studies showed considerable variability in device evaluation methods. To address this, this review recommends adopting established standards from ISO, IEC and ASTM International. The proposed framework covers the key domains: manufacturing specifications, mechanical performance, sterilisation, biocompatibility and usability. Implementation of this structured approach may enhance standardisation and support the development of safer devices.</p>","PeriodicalId":94015,"journal":{"name":"Frontiers in medical technology","volume":"8 ","pages":"1908227"},"PeriodicalIF":4.6,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13579019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148993141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overview of research and practice progress in body composition measurement techniques. 体成分测量技术的研究与实践进展综述。
IF 4.6
Frontiers in medical technology Pub Date : 2026-08-28 eCollection Date: 2026-01-01 DOI: 10.3389/fmedt.2026.1789046
Wenjuan Jing, Wenrong Jing, Shili Luo, Yinhong Chen, Qinghuan Guo, Juan Yang
{"title":"Overview of research and practice progress in body composition measurement techniques.","authors":"Wenjuan Jing, Wenrong Jing, Shili Luo, Yinhong Chen, Qinghuan Guo, Juan Yang","doi":"10.3389/fmedt.2026.1789046","DOIUrl":"10.3389/fmedt.2026.1789046","url":null,"abstract":"<p><p>The measurement of body composition is one of the most important tools for evaluating an individual's health and nutritional status. Its field has developed rapidly in recent years due to technological advances and growing application needs. Currently, widely used measurement methods include dual-energy x-ray absorptiometry (DXA), bioelectrical impedance analysis (BIA), Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and smartphone software based on Computer Vision (CV) and Artificial Intelligence (AI). Each method has its own advantages in terms of accuracy and convenience. However, these techniques still face problems related to measurement reliability and applicability across different populations. The purpose of this paper is to provide a comprehensive overview of the technologies, target populations, and research fields related to body composition measurement. Body composition measurement is an important part of health management, non-communicable disease management, clinical medicine, and sports and physical training. Along with new scientific advances, this article also presents potential future research directions in body composition measurement.</p>","PeriodicalId":94015,"journal":{"name":"Frontiers in medical technology","volume":"8 ","pages":"1789046"},"PeriodicalIF":4.6,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13563127/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148957737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书